Press Release
17 November 2026 09:00:00 CET

Newbury Pharmaceuticals' international business receives orders worth approximately SEK 14.5 million

Newbury Pharmaceuticals has received orders from two distributors in Iraq with a combined value of approximately SEK 14.5 million (USD 1.44 million).

The orders cover injectable hospital products and will be imported under the import approvals from the Iraqi Ministry of Health announced on 26 October 2026. In that release, Newbury stated that it would inform the market once orders had been confirmed.

> *"These orders show that the import approvals are already turning into business, and they confirm the demand we see for our hospital portfolio in Iraq," says Karl Karlsson, CEO of Newbury Pharmaceuticals.*

For more information, contact:

Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals' international business receives orders worth approximately SEK 14.5 million